EUVIMEDEUVIMED entdecken
Crossref

Asymmetric Dimethylarginine and NT-proBNP Levels Provide Synergistic Information in Pulmonary Arterial Hypertension

Inbal Shafran, Victoria Probst, Adelheid Panzenböck, Roela Sadushi-Kolici, Christian Gerges, Michael Wolzt, Michael J Segel, David S Celermajer, Irene Marthe Lang, Nika Skoro-Sajer

JACC: Heart Failure · 2024

DOI: 10.1016/j.jchf.2024.02.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Heart Failure, 2024. Verfasst von Inbal Shafran und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine II, Vienna General Hospital, Medical University of Vienna, Vienna, Austria; Pulmonary Institu…. Hauptthemen laut MEDLINE: Natriuretic Peptide, Brain, Arginine, Peptide Fragments, Biomarkers. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Plasma asymmetric dimethylarginine (ADMA) is elevated in pulmonary arterial hypertension (PAH) and is associated with unfavorable outcomes. OBJECTIVES: The aim of this study was to assess changes in ADMA plasma levels for monitoring disease progression and outcomes during PAH-specific therapy. METHODS: ADMA was measured at baseline and after at least 6 months of follow-up using enzyme-linked immunosorbent assay and high-performance liquid chromatography. Changes in ADMA were analyzed in relation to changes in established PAH markers, including hemodynamic status, N-terminal pro-brain natriuretic peptide (NT-proBNP) and risk assessment scores. Impact on survival was assessed using Kaplan-Meier curves and Cox proportional hazards models. RESULTS: Between 2008 and 2019, ADMA samples were collected prospectively from 215 patients with PAH. Change in ADMA plasma level was a predictor of disease progression and survival. ΔADMA (median -0.03 μmol/L; 95% CI: -0.145 to 0.0135) was correlated with change in mean pulmonary arterial pressure (P < 0.005; rS = 0.287) but was not significantly correlated with ΔNT-proBNP (P = 0.056; rS = 0.135). Patients with decreased ADMA plasma levels at follow-up had better 3-year and 5-year survival rates (88% and 80%, respectively, vs 72% and 53% in those without decreases in ADMA) (P < 0.005; pulmonary hypertension-related mortality or lung transplantation). Patients with decreases in both ADMA and NT-proBNP had better survival rates compared with patients in whom only 1 parameter improved (P < 0.005). ΔADMA was a significant predictor of survival in Cox regression analysis and also when corrected for ΔNT-proBNP (HRs: 1.27 and 1.35, respectively; P < 0.005). CONCLUSIONS: ADMA and NT-proBNP provide synergistic prognostic information for patients with PAH. ADMA could be used as an objective and distinct biomarker for monitoring treatment response in PAH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Natriuretic Peptide, BrainArgininePeptide FragmentsBiomarkersPulmonary Arterial HypertensionDisease ProgressionHumansFemaleMaleMiddle AgedProspective StudiesAdultPrognosisAgedHypertension, Pulmonary

Stichwörter der Autor:innen

ADMANT-proBNPPAHsurvival

Substanzen

Natriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)ArgininePeptide FragmentsN,N-dimethylarginineBiomarkers

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine II, Vienna General Hospital, Medical University of Vienna, Vienna, Austria; Pulmonary Institute, Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel; Faculty of…
  • Division of Cardiology, Department of Internal Medicine II, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
  • Department of Clinical Pharmacology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
  • Pulmonary Institute, Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Sydney Medical School, University of Sydney, Sydney, Australia.
  • Division of Cardiology, Department of Internal Medicine II, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. Electronic address: nika.skoro-sajer@meduniwien.ac.at.

Zitieren

APA

Shafran, I., Probst, V., Panzenböck, A., Sadushi-Kolici, R., Gerges, C., Wolzt, M., Segel, M. J., Celermajer, D. S., Lang, I. M., & Skoro-Sajer, N. (2024). Asymmetric Dimethylarginine and NT-proBNP Levels Provide Synergistic Information in Pulmonary Arterial Hypertension. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2024.02.013

Vancouver

Shafran I, Probst V, Panzenböck A, Sadushi-Kolici R, Gerges C, Wolzt M, et al. Asymmetric Dimethylarginine and NT-proBNP Levels Provide Synergistic Information in Pulmonary Arterial Hypertension. JACC: Heart Failure. 2024. doi:10.1016/j.jchf.2024.02.013

BibTeX
@article{Shafran2024,
  author = {Shafran, Inbal and Probst, Victoria and Panzenböck, Adelheid and Sadushi-Kolici, Roela and Gerges, Christian and Wolzt, Michael and Segel, Michael J and Celermajer, David S and Lang, Irene Marthe and Skoro-Sajer, Nika},
  title = {Asymmetric Dimethylarginine and NT-proBNP Levels Provide Synergistic Information in Pulmonary Arterial Hypertension},
  journal = {JACC: Heart Failure},
  year = {2024},
  doi = {10.1016/j.jchf.2024.02.013}
}
Kostenlos starten →